Table 2 The clinical trials of immune checkpoint inhibitors

From: Signaling pathways in brain tumors and therapeutic interventions

Number

Treatment

Type of Study

Setting

N of patients

NCT02337686

Pembrolizumab

Phase II

Recurrent glioblastoma (rGBM)

20

NCT02667587

Nivolumab

Phase III

Newly diagnosed MGMT-methylated GBM

716

NCT02617589

Nivolumab

Phase III

Newly diagnosed MGMT-unmethylated GBM

560

NCT03047473

Adjuvant avelumab

Phase II

Newly diagnosed GBM

30

NCT02852655

Neoadjuvant pembrolizumab

Phase I

Surgically accessible recurrent/progressive GBM

25

NCT02974621

Cediranib

Phase II

rGBM

70

NCT03197506

Neoadjuvant pembrolizumab combined with adjuvant

RT/TMZ/pembrolizumab

Phase II

Newly diagnosed GBM

50

NCT03158389

Matches one of 7 drugs to patients (APG101,

idasanutlin,alectinib, vismodegib, atezolizumab,

Palbociclib, and temsirolimus) in view of

molecular markers after surgery.

Phase I/II

MGMT-unmethylated GBM

350

NCT03174197

Atezolizumab

Phase I/II

Newly diagnosed GBM

80

NCT03925246

Nivolumab

Phase II

Recurrent IDH mutant GBM

43

NCT03341806

Avelumab

Phase I

rGBM

13

NCT03426891

Pembrolizumab

Phase I

Newly diagnosed GBM

21

NCT04323046

Ipilimumab/nivolumab+adjuvant nivolumab

Phase I

Recurrent/progressive high-grade glioma

45

NCT03532295

Epacadostat+INCMGA00012

Phase II

rGBM

55

NCT03718767

Adjuvant nivolumab

Phase II

IDH mutant glioma

95

NCT03899857

pembrolizumab

Phase II

newly diagnosed GBM

56

NCT03493932

Nivolumab with BMS-986016

Phase I

rGBM

20

NCT03961971

MBG453 + Spartalizumab

Phase I

rGBM

15

NCT04047706

BMS 986,205+ nivolumab

Phase I

Newly diagnosed GBM

30

NCT04145115

ipilimumab+nivolumab

Phase II

Somatically hypermutated glioblastoma

37

NCT04225039

schedule

Phase II

rGBM

32

NCT04826393

ASP8374 + cemiplimab

Phase Ib

Recurrent high-grade glioma

24

NCT04396860

ipilimumab

nivolumab

Phase II/III

Newly diagnosed IDH wild type MGMT-unmethylated

glioblastoma.

485

NCT04608812

OS2966

Phase I

Newly diagnosed GBM

24

NCT04729959

Tocilizumab±atezolizumab

Phase II

rGBM

12

NCT04817254

ipilimumab

Phase II

Newly diagnosed GBM or gliosarcoma

48

NCT04656535

AB154 + AB122

Phase 0/I

rGBM

46

NCT04922723

daratumumab

Phase I/II

Newly diagnosed GBM

16

NCT04952571

Camrelizumab+ bevacizumab

Phase II

rGBM

94

Back to article page